# US 2021/0275515 A1 · Method of Treating Urothelial Carcinoma and Other Genitourinary Malignancies Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275515 A1
- Document ID: US20210275515A1
- Status: Published application
- Kind: A1
- Application number: 16/336,724
- Filed: 2017-09-27
- Published: 2021-09-09
- Earliest claimed: 2016-09-27
- Assignees: The U.S. of America, as represented by the Secretary, Dept. of Health & Human Services
- Applicants: The US of America As Represented By The Secretary, Dept. of Health and Human Services
- Inventors: Andrea B. Apolo
- Web page: https://patentgrep.com/patent/US20210275515A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/868: {kidney}
- A61K 2039/884: {prostate}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to a method of treating urothelial carcinoma using Cabozantinib, a kinase inhibitor.

## Claims

### Claim 1

A method of treating a cancer selected from the group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, squamous cell carcinoma of the bladder, squamous cell carcinoma, urachal adenocarcinoma, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer, comprising administering to a patient in need of such treatment Cabozantinib, or a pharmaceutically acceptable salt thereof, in combination with one or more therapeutic agents selected from the group consisting of an anti-CTLA4 monoclonal antibody or an IgG4 anti-PD-1 monoclonal antibody or both an anti-CTLA4 monoclonal antibody and an IgG4 anti-PD-1; wherein the structure of Cabozantinib is:

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is selected from urothelial cancer, squamous cell carcinoma of the bladder, squamous cell carcinoma, urachal adenocarcinoma, and penile cancer.

### Claim 3 (depends on 1, 2)

The method of claims 1-2, wherein the cancer is metastatic urothelial carcinoma.

### Claim 4 (depends on 1, 2, 3)

The method of claims 1-3, wherein the Cabozantinib or pharmaceutically acceptable salt thereof is administered as a malate salt.

### Claim 5 (depends on 1, 2, 3, 4)

The method of claims 1-4, wherein the Cabozantinib or pharmaceutically acceptable salt thereof is administered as the (S)-malate salt.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of claims 1-5, wherein Cabozantinib (S)-malate is administered as a tablet comprising Cabozantinib (S)-malate, microcrystalline cellulose, anhydrous lactose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide magnesium stearate, and film coating comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of claims 1-6, wherein the Cabozantinib (S)-malate is administered as a tablet formulation comprising approximately:
30-32 percent by weight of Cabozantinib, (S)-malate salt;
38-40 percent by weight of microcrystalline cellulose;
18-22 percent by weight of lactose;
2-4 percent by weight of hydroxypropyl cellulose;
4-8 percent by weight of croscarmellose sodium;
0.2-0.6 percent by weight of colloidal silicon dioxide;
0.5-1 percent by weight of magnesium stearate; and further comprising:
a film coating material comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of claims 1-7, wherein the Cabozantinib (S)-malate is administered as a tablet formulation comprising approximately (% w/w):
31-32 percent by weight of Cabozantinib, (S)-malate salt;
39-40 percent by weight of microcrystalline cellulose;
19-20 percent by weight of lactose;
2.5-3.5 percent by weight of hydroxypropyl cellulose;
5.5-6.5 percent by weight of croscarmellose sodium;
0.25-0.35 percent by weight of colloidal silicon dioxide;
0.7-0.8 percent by weight of magnesium stearate; and further comprising:
3.9-4.1 percent by weight of a film coating material comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of claims 1-8, wherein the Cabozantinib or pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 20, 40, or 60 mg of Cabozantinib.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of claims 1-8, wherein the Cabozantinib or pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 20 mg of Cabozantinib.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of claims 1-8, wherein the Cabozantinib or pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 40 mg of Cabozantinib.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of claims 1-8, wherein the Cabozantinib or pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 60 mg of Cabozantinib.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of claims 1-12, wherein the anti-CTLA4 monoclonal antibody is nivolumab.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of claims 1-13, wherein the IgG4 anti-PD-1 monoclonal antibody is ipilimumab.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of claims 1-14 wherein the dose of cabozantinib or a pharmaceutically acceptable salt thereof is 40 mg once daily and the dose of nivolumab is 3 mg/kg once daily.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of claims 1-14 wherein the dose of cabozantinib or a pharmaceutically acceptable salt thereof is 40 mg once daily, the dose of nivolumab is 3 mg/kg once daily, and the dose of ipilimumab is 1 mg/kg once daily.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of claims 1-16, wherein the patient has undergone prior cancer treatment.

### Claim 18

The use of cabozantinib or a pharmaceutically acceptable salt thereof for the treatment of a cancer selected from the group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, bladder squamous cell carcinoma of the bladder, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer.

### Claim 19

The use of a combination of cabozantinib or a pharmaceutically acceptable salt thereof and nivolumab for the treatment of a cancer selected from group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, bladder squamous cell carcinoma of the bladder, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer.

### Claim 20

The use of a combination of cabozantinib or a pharmaceutically acceptable salt thereof and nivolumab and ipilimumab for the treatment of a cancer selected from group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, bladder squamous cell carcinoma of the bladder, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer.

### Claim 21 (depends on 18, 19, 20)

The uses of claims 18-20, wherein Cabozantinib or a pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 20, 40, or 60 mg of Cabozantinib.

### Claim 22 (depends on 18, 19, 20)

The uses of claims 18-20, wherein Cabozantinib or a pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 20 mg of Cabozantinib.

### Claim 23 (depends on 18, 19, 20)

The uses of claims 18-20, wherein Cabozantinib or a pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 40 mg of Cabozantinib.

### Claim 24 (depends on 18, 19, 20)

The uses of claims 18-20, wherein Cabozantinib or a pharmaceutically acceptable salt thereof is administered as a tablet formulation containing 60 mg of Cabozantinib.

### Claim 25 (depends on 19, 20)

The uses of claims 19-20, wherein the dose of Cabozantinib or a pharmaceutically acceptable salt thereof is 40 mg once daily and the dose of Nivolumab is 3 mg/kg once daily.

### Claim 26 (depends on 19, 20)

The uses of claims 19-20, wherein the dose of Cabozantinib or a pharmaceutically acceptable salt thereof is 40 mg once daily, the dose of Nivolumab is 3 mg/kg once daily, and the dose of Ipilimumab is 1 mg/kg once daily.

### Claim 27 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The uses of claims 18-26, wherein cabozantinib is administered as a malate salt.

### Claim 28 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The uses of claims 18-26, wherein cabozantinib is administered as the (S)-malate salt.
